Health Robotics chooses Device Technologies Australia as its exclusive CytoCare partner for Oceania

Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Device Technologies Australia Pty Ltd. for its revolutionary CytoCare(TM) Robot. This strategic agreement enables Device Technologies Australia to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. Admixtures to complement its other market-leading Oncology and Surgery Robotic solutions.

CytoCare is the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures. While other companies have for many years made promises of robotic IV automation products, and even showcased marketing demonstrations of competing solutions that were supposed to exist as far back twenty years ago, the fact remains that CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous IV Admixtures, and that has been proven to work in a "live" hospital pharmacy environment, instead of just marketing brochures and trade-shows demos.

"We are thrilled to have been chosen by Health Robotics as their exclusive CytoCare partner for Oceania. CytoCare, a-one-of-its-kind solution, represents an ideal complement to our market-leading CyberKnife(R) and da Vinci(R) Surgical System robotic solutions. We are very impressed by the introductory work that a small foreign company like Health Robotics has been able to do in both Australia and New Zealand, and are eager to take the "baton" from Health Robotics and continue their work in our core markets, expanding the reach of CytoCare to other hospitals in Oceania", stated Peter Ord, CEO of Device Technologies Australia."

Device Technologies believes that CytoCare has the potential to become the gold standard for Oncology I.V. Admixtures in Oceania, equally protecting clinicians and patients. The successful installation of CytoCare at Peter McCallum Cancer Centre in Melbourne has generated a tremendous amount of interest for this revolutionary technology in both Australia and New Zealand, with the real potential to significantly improve Oceania patients' immediate access to new Oncology protocols especially outside of Sydney and Melbourne, breaking this continent's inefficient reliance on IV Outsourcing, with its inherent high cost, inconvenient logistics, and limited availability of breakthrough IV therapies for cancer patients.

"Device Technologies is the right type of strategic partner for Health Robotics in Oceania due to its well known commitment to patient safety, company stability and market footprint, world-class service infrastructure and complementary oncology surgery robotic technologies. The Device Technologies Team represents a knowledgeable, highly-skilled, committed, resourceful, and customer-focused organization, which is precisely what Health Robotics requires at this moment in time to take CytoCare to the next level of market acceptance and customer-service focus in Oceania from the initial steps we undertook with Peter McCallum Cancer Centre's installation of CytoCare at the beginning of 2009", stated Werner Rainer, CEO of Health Robotics.

http://www.health-robotics.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Terminally exhausted T cells may remain competent for transcription, researchers say